help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zerwekh, J. E.
Right arrow Articles by Pak, C. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zerwekh, J. E.
Right arrow Articles by Pak, C. Y.

Journal of Clinical Endocrinology & Metabolism, Vol 60, 615-617, Copyright © 1985 by Endocrine Society


ARTICLES

Short-term 1,25-dihydroxyvitamin D3 administration raises serum osteocalcin in patients with postmenopausal osteoporosis

JE Zerwekh, K Sakhaee and CY Pak

In order to evaluate whether 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] could increase the serum concentration of osteocalcin (BGP) in patients with post-menopausal osteoporosis, we administered 2 micrograms/d of 1,25(OH)2D3 to 14 patients with biopsy proven osteoporosis for two weeks. An additional 13 age and sex-matched patients with osteoporosis received no drug and served as the control. Administration of 1,25(OH)2D3 significantly increased the serum concentration of 1,25(OH)2D from 31 +/- 2 SE to 56 +/- 5 pg/ml (p less than 0.01). Commensurate with the rise in 1,25(OH)2D was a significant increase in BGP from 3.9 +/- 0.6 to 6.4 +/- 0.9 ng/ml (p less than 0.001). There were no significant changes for these parameters in the control group. It is concluded that short term 1,25(OH)2D3 administration is effective in raising BGP concentrations in patients with post-menopausal osteoporosis.


This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
P. R. Ebeling, J. D. Wark, S. Yeung, C. Poon, N. Salehi, G. C. Nicholson, and M. A. Kotowicz
Effects of Calcitriol or Calcium on Bone Mineral Density, Bone Turnover, and Fractures in Men with Primary Osteoporosis: A Two-Year Randomized, Double Blind, Double Placebo Study
J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4098 - 4103.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
S. Mazzaferro, S. Chicca, M. Pasquali, F. Zaraca, P. Ballanti, F. Taggi, G. Coen, G. A. Cinotti, and M. Carboni
Changes in bone turnover after parathyroidectomy in dialysis patients: role of calcitriol administration
Nephrol. Dial. Transplant., June 1, 2000; 15(6): 877 - 882.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1985 by The Endocrine Society